Intracellular fluorogenic supramolecular assemblies for self-reporting bioorthogonal prodrug activation
Source abstract
Abstract
A visual drug delivery system (DDS) is urgently needed for precision medicine. DDS-mediated bioorthogonal prodrug activation strategies have demonstrated remarkable advantages in enlarging a therapeutic index via the alleviation of adverse drug reactions. However, the events of bioorthogonal prodrug activation remain inaccessible. Here, we construct a self-reporting bioorthogonal prodrug activation system using fluorescence emission to interpret prodrug activation events. In designed reactive oxygen species (ROS)-instructed supramolecular assemblies, the bioorthogonal reaction handle of tetrazine carries a dual role as fluorescence quencher and prodrug activator. The subsequent inverse-electron-demand Diels-Alder (IEDDA) reaction simultaneously liberates fluorescence and active drugs, which form a linear relationship. Differentiated by their cellular redox status, ROS-instructed supramolecular assemblies form selectively in both tumor cells and cell spheroids. Upon prodrug treatment, the brightness of fluorescence reflects the liberation of active drugs, which further correlates with the cell survival rate. Therefore, a fluorescence-based visualizable DDS (VDDS) for bioorthogonal prodrug activation is demonstrated, which should be useful to elucidate the multi-step processes in drug delivery and determine prodrug activation efficacy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Click Chemistry and Applications · Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CAS Center for Excellence in Nanoscience, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100190, China
Funding
Key Research Program of Frontier Science, Chinese Academy of Sciences · National Natural Science Foundation of China
References (48)
Show source-provided references
1. Rad · Adv. Mater. · 2021 · 33 · e200536310.1002/adma.202005363 ↗
2. Chen · Nat. Rev. Mater. · 2017 · 2 · 1702410.1038/natrevmats.2017.24 ↗
3. Geiselhart · Angew. Chem., Int. Ed. · 2021 · 60 · 1729010.1002/anie.202012592 ↗
4. Xie · Adv. Drug Delivery Rev. · 2010 · 62 · 106410.1016/j.addr.2010.07.009 ↗
5. Anglin · Adv. Drug Delivery Rev. · 2008 · 60 · 126610.1016/j.addr.2008.03.017 ↗
6. Vallet-Regi · Angew. Chem., Int. Ed. · 2007 · 46 · 754810.1002/anie.200604488 ↗
7. Ngen · Int. J. Mol. Sci. · 2017 · 18 · 19810.3390/ijms18010198 ↗
8. Chen · Adv. Sci. · 2020 · 7 · 190378310.1002/advs.201903783 ↗
9. Ji · Adv. Drug Delivery Rev. · 2020 · 167 · 12110.1016/j.addr.2020.06.012 ↗
10. Lee · Chem. Soc. Rev. · 2018 · 47 · 2810.1039/C7CS00557A ↗
11. Xing · Nanoscale · 2020 · 12 · 2431110.1039/D0NR06867E ↗
12. Mura · Nat. Mater. · 2013 · 12 · 99110.1038/nmat3776 ↗
13. Zhao · Cell · 2020 · 181 · 15110.1016/j.cell.2020.02.001 ↗
14. Ghosh · Adv. Drug Delivery Rev. · 2008 · 60 · 130710.1016/j.addr.2008.03.016 ↗
15. Maiti · J. Am. Chem. Soc. · 2013 · 135 · 456710.1021/ja401350x ↗
16. He · Chem. Rev. · 2020 · 120 · 999410.1021/acs.chemrev.0c00306 ↗
17. Dudani · Annu. Rev. Cancer Biol. · 2018 · 2 · 35310.1146/annurev-cancerbio-030617-050549 ↗
18. Zhou · Chem · 2016 · 1 · 24610.1016/j.chempr.2016.07.003 ↗
19. Schmaljohann · Adv. Drug Delivery Rev. · 2006 · 58 · 165510.1016/j.addr.2006.09.020 ↗
20. Chen · Small · 2020 · 16 · e200278010.1002/smll.202002780 ↗
21. Rautio · Nat. Rev. Drug Discovery · 2008 · 7 · 25510.1038/nrd2468 ↗
22. Ulbrich · Chem. Rev. · 2016 · 116 · 533810.1021/acs.chemrev.5b00589 ↗
23. Ettmayer · J. Med. Chem. · 2004 · 47 · 239310.1021/jm0303812 ↗
24. Li · Nat. Chem. Biol. · 2016 · 12 · 12910.1038/nchembio.2024 ↗
25. Ji · Chem. Soc. Rev. · 2019 · 48 · 107710.1039/C8CS00395E ↗
26. Yao · Nat. Commun. · 2018 · 9 · 503210.1038/s41467-018-07490-6 ↗
27. Wang · ACS Cent. Sci. · 2021 · 7 · 92910.1021/acscentsci.1c00124 ↗
28. Yao · Biomaterials · 2021 · 277 · 12111910.1016/j.biomaterials.2021.121119 ↗
29. Ji · Angew. Chem., Int. Ed. · 2016 · 55 · 1584610.1002/anie.201608732 ↗
30. Zheng · Nat. Chem. · 2018 · 10 · 78710.1038/s41557-018-0055-2 ↗
31. Du · Chem · 2020 · 6 · 206010.1016/j.chempr.2020.06.002 ↗
32. You · Nat. Commun. · 2022 · 13 · 145910.1038/s41467-022-29167-x ↗
33. Wang · Nature · 2020 · 579 · 42110.1038/s41586-020-2079-1 ↗
34. Qin · Adv. Mater. · 2021 · 33 · e200600710.1002/adma.202006007 ↗
35. Carlson · J. Am. Chem. Soc. · 2018 · 140 · 360310.1021/jacs.7b11217 ↗
36. Versteegen · Angew. Chem., Int. Ed. · 2018 · 57 · 1049410.1002/anie.201800402 ↗
37. Wilkovitsch · J. Am. Chem. Soc. · 2020 · 142 · 1913210.1021/jacs.0c07922 ↗
38. Devaraj · Angew. Chem., Int. Ed. · 2010 · 49 · 286910.1002/anie.200906120 ↗
39. Pinto-Pacheco · Angew. Chem., Int. Ed. · 2020 · 59 · 2214010.1002/anie.202008757 ↗
40. Carlson · Angew. Chem., Int. Ed. · 2013 · 52 · 691710.1002/anie.201301100 ↗
41. Huang · Chem. Commun. · 2018 · 54 · 538510.1039/C8CC02648C ↗
42. Huang · Biomaterials · 2020 · 253 · 12012410.1016/j.biomaterials.2020.120124 ↗
43. Chen · Biomed. Mater. · 2021 · 16 · 02201110.1088/1748-605X/abc2e9 ↗
44. Dumas-Verdes · Eur. J. Org. Chem. · 2010 · 252510.1002/ejoc.200900874 ↗
45. Szatrowski · Cancer Res. · 1991 · 51 · 794
46. Trachootham · Nat. Rev. Drug Discovery · 2009 · 8 · 57910.1038/nrd2803 ↗
47. Ishikawa · Science · 2008 · 320 · 66110.1126/science.1156906 ↗
48. Liu · Chem. Sci. · 2019 · 11 · 113210.1039/C9SC04317A ↗